ANIX (Anixa Biosciences) Current Accrued Expense: $1.21 Mil (As of Apr. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIX Anixa Biosciences Inc ANIX
32 GF Score
Price $3.71
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Current Accrued Expense?

Anixa Biosciences ANIX +7.85% 32 Current Accrued Expense is $1.21 Mil as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Anixa Biosciences's Current Accrued Expense for the quarter that ended in Apr. 2026 was $1.21 Mil.

Anixa Biosciences's quarterly Current Accrued Expense declined from Oct. 2025 ($1.76 Mil) to Jan. 2026 ($1.05 Mil) but then increased from Jan. 2026 ($1.05 Mil) to Apr. 2026 ($1.21 Mil).

Anixa Biosciences's annual Current Accrued Expense increased from Oct. 2023 ($1.77 Mil) to Oct. 2024 ($1.95 Mil) but then declined from Oct. 2024 ($1.95 Mil) to Oct. 2025 ($1.76 Mil).

Anixa Biosciences Current Accrued Expense Related Terms

Anixa Biosciences Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Current Accrued Expense Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.10 1.73 1.77 1.95 1.76

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.57 1.75 1.76 1.05 1.21
ANIX
32GF Score
Anixa Biosciences Inc ANIX
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $1.21 Mil mean?
Anixa Biosciences (ANIX) has a Current Accrued Expense of $1.21 Mil as of Apr. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' Current Accrued Expense too high?
Anixa Biosciences' current Current Accrued Expense is $1.21 Mil. Overall, Anixa Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Current Accrued Expense compare to GUTS and CBUS?
Anixa Biosciences' Current Accrued Expense of $1.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Current Accrued Expense is $1.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Current Accrued Expense of $1.21 Mil. The current Current Accrued Expense is $1.21 Mil. Anixa Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Current Accrued Expense is $1.21 Mil as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
32GF Score

Get the complete analysis for ANIX

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.71
Price